Perspective Therapeutics Inc. Common Stock (CATX)
Stock · AMEX · Health Care
$3.11as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$2.93
Industry
Medical/Dental Instruments
About CATX
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previous…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 163
Fundamentals
- 1-day range
- $3.08$3.17
- Market cap
- $343.28M
- P/E (trailing)
- —
- P/E (forward)
- -3.05
- EPS (trailing)
- $-1.40
- Dividend yield
- —
- Beta
- 1.80
- Avg. volume
- 1.65M
52-week range
$1.96$6.16
Next earnings: November 9, 2026 · EPS estimate $-0.25
Forecasts
15 analyst ratings
Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$18
+478.8%
Median
$13
+318.0%
Low
$5
+60.8%
Perspective Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CATXPerspective Therapeutics Inc. Common Stock$3.1▼ 2.67%Market cap $343.28MP/E —$1.96$6.16
- MOBIMobia Medical Inc. Common Stock$11.37▲ 7.22%Market cap $377.38MP/E —$10.19$15.29
- TMCITreace Medical Concepts Inc. Common Stock$4.67▲ 1.41%Market cap $303.61MP/E —$1.17$7.63
- PROFProfound Medical Corp. Common Stock$6.86▼ 1.44%Market cap $299.42MP/E —$5.23$12.4
- NPCENeuropace Inc. Common Stock$14.41▲ 1.98%Market cap $460.27MP/E —$8.76$19.6
- PDEXPro-Dex Inc. Common Stock$62.37▼ 3.85%Market cap $203.09MP/E 17.93$23.47$69.86
- LUCDLucid Diagnostics Inc. Common Stock$0.9989▲ 1.51%Market cap $196.65MP/E —$0.8605$1.63
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CATX Perspective Therapeutics Inc. Common Stock | $343.28M | — | $3.1 | ▼ 2.67% | $1.96$6.16 |
| MOBI Mobia Medical Inc. Common Stock | $377.38M | — | $11.37 | ▲ 7.22% | $10.19$15.29 |
| TMCI Treace Medical Concepts Inc. Common Stock | $303.61M | — | $4.67 | ▲ 1.41% | $1.17$7.63 |
| PROF Profound Medical Corp. Common Stock | $299.42M | — | $6.86 | ▼ 1.44% | $5.23$12.4 |
| NPCE Neuropace Inc. Common Stock | $460.27M | — | $14.41 | ▲ 1.98% | $8.76$19.6 |
| PDEX Pro-Dex Inc. Common Stock | $203.09M | 17.93 | $62.37 | ▼ 3.85% | $23.47$69.86 |
| LUCD Lucid Diagnostics Inc. Common Stock | $196.65M | — | $0.9989 | ▲ 1.51% | $0.8605$1.63 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 77.26M
- Total value held
- $321.68M
- Institutional holders
- 132
Top holders this quarter
- Unknown7.92M
- Unknown6.34M
- Unknown6.05M
- Unknown5.35M
- Unknown4.67M
- Unknown4.38M
- Unknown4.05M
- Unknown3.64M
- Unknown3.16M
- Unknown3.13M
See the full, filterable feed with live charts on the MarketWall dashboard.